Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone for proteinuria reduction in pediatric complicated nephrotic syndrome
IRCT20260511069359N1Phase 2Recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pioglitazone in nephrosis, sponsored by Tehran University of Medical Sciences. Primary endpoints: Reduction in proteinuria and Change in urine protein-to-creatinine ratio. Started Jun 2026; status: recruiting.
02
Drugs
pioglitazone
03
Conditions
nephrosis
Beyond the preview
Go deeper on IRCT20260511069359N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260511069359N1.